An interventional study of Dual-Action Myopia-Control Spectacle Lens and Stellest Myopia-Control Spectacle Lens(Highly Aspherical Lenslet Target / HALT Lens) in Myopia and Refractive Errors, sponsored by Shanghai Eye Disease Prevention and Treatment Center. Not yet recruiting at 1 site in China. Open to participants aged 6 Years to 14 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-02.
Sponsored by Shanghai Eye Disease Prevention and Treatment Center · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 42 studies in Myopia by Shanghai Eye Disease Prevention and Treatment Center — 21 open to participants now, 22 under way, none of them phase 3. Myopia · Shanghai Eye Disease Prevention and Treatment Center.
Among the 42 studies in Myopia by Shanghai Eye Disease Prevention and Treatment Center, this one is the 23rd largest by planned enrollment of the 36 interventional ones that give a count, is one of 10 that started in 2026, is one of 32 with no phase, reaches primary completion later than 17 of the 21 other live ones, and was the 41st registered.
1,165 studies on the registry are indexed under Myopia; 228 are open to participants now.
Browse Myopia studies →21 of the 42 studies in Myopia by Shanghai Eye Disease Prevention and Treatment Center are open now, in 1 country. Recruiting first, the newest first:
Shanghai Eye Disease Prevention and Treatment Center · Sites in China
Ages 3–6
Shanghai Eye Disease Prevention and Treatment Center · Sites in China
Ages 6–11 · Healthy volunteers
Shanghai Eye Disease Prevention and Treatment Center · Sites in China
Ages 6–11
Shanghai Eye Disease Prevention and Treatment Center · Sites in China
Ages 6–11 · Healthy volunteers
Shanghai Eye Disease Prevention and Treatment Center · Sites in China
Ages 18–55
By country, each count listing its studies:
Of the 124 Myopia studies recruiting now, 20 (16%) set no upper age limit and 103 (83%) stop at 75 or younger; 85 take children under 18; 53 take healthy volunteers.
This study: 6 Years to 14 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
42 studies; the count open now beside each. This study's row is marked.
First in 2016; this study’s year is marked. 10 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 120 is above the median of 79 across 929 interventional studies indexed under Myopia.
Median enrollment 141 across the 36 interventional studies, 9,500 across the 6 observational. Of the 8 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Shanghai Eye Disease Prevention and Treatment Center is the lead sponsor of 67 studies on the registry; 31 are open to participants now.
9 of the studies in Myopia by Shanghai Eye Disease Prevention and Treatment Center that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05770661Shanghai Eye Disease Prevention and Treatment CenterChina Children Eye Study | 2026-12-31 |
| NCT07746804Shanghai Eye Disease Prevention and Treatment CenterSchool-based Myopia Prevention Trial for Children With Insufficient Hyperopic Reserve | 2027-06 |
| NCT07746752Shanghai Eye Disease Prevention and Treatment CenterSchool-based Myopia Prevention Trial for Children With Adequate Hyperopic Reserve | 2027-06 |
| NCT07746778Shanghai Eye Disease Prevention and Treatment CenterSchool-based Myopia Control Trial for Children With Premyopia or Myopia | 2027-06 |
| NCT07176949Shanghai Eye Disease Prevention and Treatment CenterEarly-Onset Myopia Intervention Project | 2027-06-01 |
Add all 9 to your calendar (.ics) → With an account.
Among the 42 studies in Myopia by Shanghai Eye Disease Prevention and Treatment Center, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a single-center, randomized, double-blind, controlled study to test whether a new type of eyeglass lens - a "dual-action" lens that combines two technologies (multiple defocus zones and dot diffusion) - can slow the progression of nearsightedness (myopia) in children and teenagers.
About the participants: Children and adolescents with myopia who meet the study requirements will be randomly assigned (like flipping a coin) to one of two groups. One group will wear the new dual-action lenses, and the other group will wear Stellest lenses, an established myopia-control lens. Neither the participants, their families, nor the eye doctors doing the follow-up exams will know which lens each child is wearing.
About the study: Participants wear their assigned glasses at least 12 hours every day for 12 months and visit the clinic about every 3 months (5 visits in total). At each visit, doctors check eyesight, measure the length of the eyeball, and perform other eye exams. The main goal is to compare how much myopia progresses in the two groups after 12 months, measured by a painless dilated-eye (cycloplegic) refraction test. The study also tracks how comfortable and acceptable the lenses are, and how long children actually wear them each day.
Why this research matters: Myopia in children is increasing worldwide, and effective ways to slow it down are still limited. This study will show whether combining two proven optical technologies in one lens works as well as existing options and is safe and comfortable for daily wear.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Device: Dual-Action Myopia-Control Spectacle Lens
Participants in this arm wear Stellest myopia-control spectacle lenses, an established myopia-control lens with highly aspherical lenslet target (HALT) technology that is already marketed. Participants are instructed to wear the assigned lenses at least 12 hours per day for 12 months. The follow-up schedule and examinations are identical to those in the experimental arm. Neither the participants, their guardians, nor the follow-up examiners know which lens is being worn.
Device: Stellest Myopia-Control Spectacle Lens(Highly Aspherical Lenslet Target / HALT Lens)
Spectacle lenses that combine two myopia-control optical technologies in a single lens: multiple defocus zones (multipoint peripheral defocus design) and dot diffusion technology (a light-scattering treatment that reduces contrast of the peripheral retinal image). The two technologies are intended to act together to slow axial elongation and myopia progression. Lenses are worn as daily-wear spectacles, with participants instructed to wear them at least 12 hours per day throughout the 12-month study period. This lens is investigational and not currently marketed.
Stellest spectacle lenses incorporate Highly Aspherical Lenslet Target (HALT) technology: a constellation of highly aspherical micro-lenslets distributed across the lens surface, which creates a volume of myopic defocus in front of the retina to slow eye growth. Lenses are worn as daily-wear spectacles, with participants instructed to wear them at least 12 hours per day throughout the 12-month study period. Stellest is an established, marketed myopia-control lens used here as the active comparator.
Change in Cycloplegic Spherical Equivalent (SE) From Baseline at 12 Months
The primary efficacy outcome is the change in spherical equivalent (SE, in diopters) measured by cycloplegic (dilated-eye) refraction from baseline to Month 12. SE is calculated as sphere + ½ × cylinder. Cycloplegic refraction is performed after administration of cycloplegic eye drops, using the same autorefractor and standardized procedure at each visit. A smaller change (less myopic shift) indicates better myopia control. The right eye is designated as the study (observation) eye.
Time frame: Baseline and Month 12
Change in Axial Length (AL) From Baseline at 12 Months
Change in axial length (mm) measured by ocular biometry (e.g., IOLMaster) from baseline to Month 12 in the study eye. A smaller increase indicates better myopia control. AL is also assessed at Months 3, 6, and 9.
Time frame: Baseline and Month 12
Corneal Curvature
Corneal curvature (K values) measured by corneal topography/keratometry at each visit, as part of routine ocular assessment.
Time frame: Baseline and Months 3, 6, 9, 12
Exploratory Analysis of Factors Associated With Myopia Progression and Myopia-Control Practice
Exploratory analysis of factors such as age at myopia onset, sex, daily wearing time, and visual habits (e.g., near-work and outdoor time), based on questionnaire data, to understand myopia-control diagnosis and treatment patterns in children and adolescents.
Time frame: Collected at baseline and throughout the 12-month study period
Plan to share: Undecided
Start is estimated for Oct 2026; primary completion for Feb 2028, 16 months later.
Of 202 non-industry interventional studies with no phase under Myopia, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 44. This study's planned 16 months is below that.
Counting every sponsor, half of 438 studies reached it within 14 months; a quarter within 3 and three quarters within 34.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Shanghai Eye Disease Prevention and Treatment Center